BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7523383)

  • 21. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
    Amacker M; Hübscher U
    J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
    Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
    Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
    Balzarini J; Karlsson A; Meichsner C; Paessens A; Riess G; De Clercq E; Kleim JP
    J Virol; 1994 Dec; 68(12):7986-92. PubMed ID: 7525984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
    Van Laethem K; Schmit JC; Pelemans H; Balzarini J; Witvrouw M; Pérez-Pérez MJ; Camarasa MJ; Esnouf RM; Aquaro S; Cenci A; Perno CF; Hermans P; Sprecher S; Ruiz L; Clotet B; Van Wijngaerden E; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
    AIDS Res Hum Retroviruses; 2000 Jun; 16(9):825-33. PubMed ID: 10875608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
    Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
    Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress.
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Bonache MC; De Castro S
    Curr Pharm Des; 2006; 12(15):1895-907. PubMed ID: 16724955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
    Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
    Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.
    Ding J; Das K; Tantillo C; Zhang W; Clark AD; Jessen S; Lu X; Hsiou Y; Jacobo-Molina A; Andries K
    Structure; 1995 Apr; 3(4):365-79. PubMed ID: 7542140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
    Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
    J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3-N- methyl-thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dio xide).
    Balzarini J; Naesens L; Bohman C; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E
    Biochem Pharmacol; 1993 Jul; 46(1):69-77. PubMed ID: 8102234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer.
    Harris D; Lee R; Misra HS; Pandey PK; Pandey VN
    Biochemistry; 1998 Apr; 37(17):5903-8. PubMed ID: 9558323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of the reverse transcriptase of human immunodeficiency virus type 1 with DNA.
    Bakhanashvili M; Hizi A
    Biochemistry; 1994 Oct; 33(40):12222-8. PubMed ID: 7522556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme.
    Tasara T; Amacker M; Hübscher U
    Biochemistry; 1999 Feb; 38(5):1633-42. PubMed ID: 9931031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity.
    Soriano E; Marco-Contelles J; Tomassi C; Nguyen Van Nhien A; Postel D
    J Chem Inf Model; 2006; 46(4):1666-77. PubMed ID: 16859298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization.
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ
    Antivir Chem Chemother; 2005; 16(3):147-53. PubMed ID: 16004078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates.
    Ueno T; Shirasaka T; Mitsuya H
    J Biol Chem; 1995 Oct; 270(40):23605-11. PubMed ID: 7559526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
    Balzarini J; Pérez-Pérez MJ; San-Félix A; Schols D; Perno CF; Vandamme AM; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1992 May; 89(10):4392-6. PubMed ID: 1374900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
    Zhang H; Vrang L; Bäckbro K; Unge T; Noréen R; Oberg B
    Antiviral Res; 1994 May; 24(1):43-57. PubMed ID: 7524439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
    Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
    Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.